Compare Gilead Sciences, Inc. (GILD) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Payoneer Global Inc — how do they compare? Gilead Sciences, Inc. trades at $135.5 (market cap $168.35B), while Payoneer Global Inc trades at $7.08 (market cap $2.40B). The key difference: Gilead Sciences, Inc. is far larger — about 70.1× Payoneer Global Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals.
| GILD | PAYO | |
|---|---|---|
Market Cap | $168.35B | $2.40B |
Sector | Health | Technology |
52-Week High | $155.80 | $7.17 |
52-Week Low | $110.56 | $4.27 |
Enterprise Value | $191.42B | $2.14B |
Dividend Yield | 2.42% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
